SK5282001A3 - Tricyclic pyrazole derivatives - Google Patents

Info

Publication number

SK5282001A3

SK5282001A3 SK528-2001A SK5282001A SK5282001A3 SK 5282001 A3 SK5282001 A3 SK 5282001A3 SK 5282001 A SK5282001 A SK 5282001A SK 5282001 A3 SK5282001 A3 SK 5282001A3

Authority

SK

Slovakia

Prior art keywords

phenyl

group

alkyl

optionally substituted

pyrazol

Prior art date

1998-11-06

Links

• Espacenet
• Global Dossier
• Discuss

• 150000003217 pyrazoles Chemical class 0.000 title abstract description 7
• 150000001875 compounds Chemical class 0.000 claims abstract description 263
• 238000000034 method Methods 0.000 claims abstract description 59
• 230000000694 effects Effects 0.000 claims abstract description 54
• 102000001253 Protein Kinase Human genes 0.000 claims abstract description 29
• 108060006633 protein kinase Proteins 0.000 claims abstract description 29
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
• -1 N- [4- (1,4-dihydroindeno [1,2-c] pyrazol-3-yl) phenyl] carbamic acid 1-methyl-2-propoxyethyl ester 1,4-dihydro-4-methyl-3-phenylpyrazolo [4,3-b] indole Chemical compound 0.000 claims description 821
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 383
• 125000000217 alkyl group Chemical group 0.000 claims description 198
• 125000001424 substituent group Chemical group 0.000 claims description 188
• 229910052739 hydrogen Inorganic materials 0.000 claims description 181
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 174
• 239000001257 hydrogen Substances 0.000 claims description 165
• 229910052736 halogen Inorganic materials 0.000 claims description 144
• 150000002367 halogens Chemical class 0.000 claims description 139
• 150000002431 hydrogen Chemical class 0.000 claims description 101
• 125000003545 alkoxy group Chemical group 0.000 claims description 97
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 85
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 80
• 229910052757 nitrogen Inorganic materials 0.000 claims description 80
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 76
• 125000004076 pyridyl group Chemical group 0.000 claims description 71
• 229910052760 oxygen Inorganic materials 0.000 claims description 66
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 64
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 53
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 52
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 52
• 125000003277 amino group Chemical group 0.000 claims description 52
• 201000010099 disease Diseases 0.000 claims description 52
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 50
• 150000003839 salts Chemical class 0.000 claims description 50
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 49
• 125000000623 heterocyclic group Chemical group 0.000 claims description 48
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 47
• 125000002541 furyl group Chemical group 0.000 claims description 47
• 125000001544 thienyl group Chemical group 0.000 claims description 47
• 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims description 41
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 39
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 38
• 125000005842 heteroatom Chemical group 0.000 claims description 37
• 229910052717 sulfur Inorganic materials 0.000 claims description 37
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 37
• 125000003118 aryl group Chemical group 0.000 claims description 36
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 36
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 34
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 32
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 32
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 32
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 30
• 239000001301 oxygen Substances 0.000 claims description 30
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 29
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 29
• KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 28
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 27
• 229910052799 carbon Inorganic materials 0.000 claims description 26
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 26
• 206010030113 Oedema Diseases 0.000 claims description 25
• 229910052731 fluorine Inorganic materials 0.000 claims description 25
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 24
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
• 230000002401 inhibitory effect Effects 0.000 claims description 24
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 23
• 230000002792 vascular Effects 0.000 claims description 23
• 125000005843 halogen group Chemical group 0.000 claims description 22
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 21
• 102000004190 Enzymes Human genes 0.000 claims description 21
• 108090000790 Enzymes Proteins 0.000 claims description 21
• 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 20
• 108091000080 Phosphotransferase Proteins 0.000 claims description 20
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 20
• 102000020233 phosphotransferase Human genes 0.000 claims description 20
• 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 20
• 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 19
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 19
• 230000015572 biosynthetic process Effects 0.000 claims description 19
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 18
• 206010028980 Neoplasm Diseases 0.000 claims description 18
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 18
• 230000033115 angiogenesis Effects 0.000 claims description 18
• 239000000460 chlorine Substances 0.000 claims description 18
• 239000003814 drug Substances 0.000 claims description 18
• 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 18
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 17
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 17
• 229910052801 chlorine Inorganic materials 0.000 claims description 17
• 239000011737 fluorine Substances 0.000 claims description 17
• 125000001624 naphthyl group Chemical group 0.000 claims description 17
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 16
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 16
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 16
• 125000005554 pyridyloxy group Chemical group 0.000 claims description 16
• 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 claims description 16
• 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 15
• 125000003368 amide group Chemical group 0.000 claims description 15
• 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 15
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 14
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 13
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 13
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 13
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 12
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 12
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 12
• 230000005764 inhibitory process Effects 0.000 claims description 12
• 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 11
• 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 11
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 11
• 201000011510 cancer Diseases 0.000 claims description 11
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 11
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 11
• 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 10
• 150000001408 amides Chemical class 0.000 claims description 10
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
• 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 9
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 9
• 229910052794 bromium Inorganic materials 0.000 claims description 9
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 claims description 9
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 claims description 9
• 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims description 8
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
• FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims description 8
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 8
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 8
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 8
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 8
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 8
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 8
• 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 8
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 8
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 8
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 8
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 8
• 239000002253 acid Substances 0.000 claims description 8
• 125000004104 aryloxy group Chemical group 0.000 claims description 8
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 8
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 8
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
• 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 8
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 8
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 8
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 8
• 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 8
• 125000005415 substituted alkoxy group Chemical group 0.000 claims description 8
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 8
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 8
• 150000003852 triazoles Chemical class 0.000 claims description 8
• 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 7
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
• 201000004681 Psoriasis Diseases 0.000 claims description 7
• 125000003342 alkenyl group Chemical group 0.000 claims description 7
• 125000003302 alkenyloxy group Chemical group 0.000 claims description 7
• 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 7
• 239000004202 carbamide Substances 0.000 claims description 7
• DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical group CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 claims description 7
• 150000003536 tetrazoles Chemical class 0.000 claims description 7
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
• OVFWJJAWVFGFRQ-UHFFFAOYSA-N 4-[2-[3-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenoxy]ethyl]morpholine Chemical compound C=1C=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=CC=1OCCN1CCOCC1 OVFWJJAWVFGFRQ-UHFFFAOYSA-N 0.000 claims description 5
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
• 206010003445 Ascites Diseases 0.000 claims description 5
• 206010063045 Effusion Diseases 0.000 claims description 5
• 206010016654 Fibrosis Diseases 0.000 claims description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims description 5
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims description 5
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
• 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 5
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 5
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
• 206010003246 arthritis Diseases 0.000 claims description 5
• JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 claims description 5
• 208000002780 macular degeneration Diseases 0.000 claims description 5
• DFXMQLGWWGYSMX-UHFFFAOYSA-N 3-thiophen-2-yl-2h-[1]benzothiolo[3,2-c]pyrazole Chemical compound C1=CSC(C=2C=3SC4=CC=CC=C4C=3NN=2)=C1 DFXMQLGWWGYSMX-UHFFFAOYSA-N 0.000 claims description 4
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 4
• 201000001320 Atherosclerosis Diseases 0.000 claims description 4
• 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims description 4
• 230000001772 anti-angiogenic effect Effects 0.000 claims description 4
• 230000001684 chronic effect Effects 0.000 claims description 4
• 208000014674 injury Diseases 0.000 claims description 4
• 229910052740 iodine Inorganic materials 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• WTNAMXIGHPHQLL-UHFFFAOYSA-N n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)acetamide Chemical compound C=1C(NC(=O)C)=CC=C2C=1CC1=C2NN=C1C1=CC=CC=C1 WTNAMXIGHPHQLL-UHFFFAOYSA-N 0.000 claims description 4
• 229920006395 saturated elastomer Polymers 0.000 claims description 4
• 230000008733 trauma Effects 0.000 claims description 4
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
• ZJZNZNMPNRNCLA-UHFFFAOYSA-N 2-[3-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenoxy]ethanol Chemical compound OCCOC1=CC=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 ZJZNZNMPNRNCLA-UHFFFAOYSA-N 0.000 claims description 3
• ROBMJUSXRQGBTM-UHFFFAOYSA-N 2-morpholin-4-yl-n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)acetamide Chemical compound C=1C=C(C=2NN=C(C=2C2)C=3C=CC=CC=3)C2=CC=1NC(=O)CN1CCOCC1 ROBMJUSXRQGBTM-UHFFFAOYSA-N 0.000 claims description 3
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
• DZQLVVLATXPWBK-UHFFFAOYSA-N 3-phenyl-1H-benzofuro[3,2-c]pyrazole Chemical compound C1=CC=CC=C1C1=NNC2=C1OC1=CC=CC=C12 DZQLVVLATXPWBK-UHFFFAOYSA-N 0.000 claims description 3
• DEDXYUREJUSWOW-UHFFFAOYSA-N 3-thiophen-2-yl-2h-indeno[1,2-c]pyrazol-4-one Chemical compound C=12C(=O)C3=CC=CC=C3C2=NNC=1C1=CC=CS1 DEDXYUREJUSWOW-UHFFFAOYSA-N 0.000 claims description 3
• MRDKBCGWHNPOFW-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 MRDKBCGWHNPOFW-UHFFFAOYSA-N 0.000 claims description 3
• 206010048962 Brain oedema Diseases 0.000 claims description 3
• LFNHUDYDNZBDNU-UHFFFAOYSA-N C1=C(OC)C(OC)=CC=C1C1=NNC2=C1C(=NO)C1=CC=CC=C12 Chemical compound C1=C(OC)C(OC)=CC=C1C1=NNC2=C1C(=NO)C1=CC=CC=C12 LFNHUDYDNZBDNU-UHFFFAOYSA-N 0.000 claims description 3
• LWYLQOXGXKHIHX-UHFFFAOYSA-N C1=CC(C)=CC=C1C1=NNC2=C1C(=NO)C1=CC=CC=C12 Chemical compound C1=CC(C)=CC=C1C1=NNC2=C1C(=NO)C1=CC=CC=C12 LWYLQOXGXKHIHX-UHFFFAOYSA-N 0.000 claims description 3
• 201000009273 Endometriosis Diseases 0.000 claims description 3
• 208000010412 Glaucoma Diseases 0.000 claims description 3
• 241000589989 Helicobacter Species 0.000 claims description 3
• 208000019693 Lung disease Diseases 0.000 claims description 3
• 206010037423 Pulmonary oedema Diseases 0.000 claims description 3
• 208000006011 Stroke Diseases 0.000 claims description 3
• 208000025865 Ulcer Diseases 0.000 claims description 3
• 208000006752 brain edema Diseases 0.000 claims description 3
• 125000001246 bromo group Chemical group Br* 0.000 claims description 3
• 230000002490 cerebral effect Effects 0.000 claims description 3
• 230000006020 chronic inflammation Effects 0.000 claims description 3
• 230000004761 fibrosis Effects 0.000 claims description 3
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
• 208000005333 pulmonary edema Diseases 0.000 claims description 3
• 208000011580 syndromic disease Diseases 0.000 claims description 3
• 230000029663 wound healing Effects 0.000 claims description 3
• ZIPCOKAORSQAAR-UHFFFAOYSA-N 1-[(2,5-difluorophenyl)methyl]-3-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]urea Chemical compound FC1=CC=C(F)C(CNC(=O)NC=2C=CC(=CC=2)C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 ZIPCOKAORSQAAR-UHFFFAOYSA-N 0.000 claims description 2
• XUALJDMCUIAHIL-UHFFFAOYSA-N 1-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-3-[1-(dimethylamino)propan-2-yl]urea Chemical compound C1=CC(NC(=O)NC(CN(C)C)C)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 XUALJDMCUIAHIL-UHFFFAOYSA-N 0.000 claims description 2
• LNJGSUPTTZFMKD-UHFFFAOYSA-N 2,2-dimethyl-n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)propanamide Chemical compound C=1C(NC(=O)C(C)(C)C)=CC=C2C=1CC1=C2NN=C1C1=CC=CC=C1 LNJGSUPTTZFMKD-UHFFFAOYSA-N 0.000 claims description 2
• CPTZZSIBRYRKOY-UHFFFAOYSA-N 2-(1,4-diazepan-1-yl)-n-phenylacetamide Chemical compound C=1C=CC=CC=1NC(=O)CN1CCCNCC1 CPTZZSIBRYRKOY-UHFFFAOYSA-N 0.000 claims description 2
• QJSAVLFUAGZCSS-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)-n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)acetamide Chemical compound C1CN(C)CCN1CC(=O)NC1=CC=C2C(NN=C3C=4C=CC=CC=4)=C3CC2=C1 QJSAVLFUAGZCSS-UHFFFAOYSA-N 0.000 claims description 2
• SAPPSFYRPKHHBM-UHFFFAOYSA-N 2-[2-(dimethylamino)ethoxy]ethyl n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]carbamate Chemical compound C1=CC(NC(=O)OCCOCCN(C)C)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 SAPPSFYRPKHHBM-UHFFFAOYSA-N 0.000 claims description 2
• PBONLAWSGLCCKD-UHFFFAOYSA-N 2-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenoxy]acetamide Chemical compound C1=CC(OCC(=O)N)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 PBONLAWSGLCCKD-UHFFFAOYSA-N 0.000 claims description 2
• XVMJKPOJAFGIPQ-UHFFFAOYSA-N 2-[ethyl(2-hydroxyethyl)amino]ethyl n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]carbamate Chemical compound C1=CC(NC(=O)OCCN(CCO)CC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 XVMJKPOJAFGIPQ-UHFFFAOYSA-N 0.000 claims description 2
• XZUCBHPUPYFPNV-UHFFFAOYSA-N 2-chloro-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenol Chemical compound C1=C(Cl)C(O)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 XZUCBHPUPYFPNV-UHFFFAOYSA-N 0.000 claims description 2
• GVQMFFMYOWZTFS-UHFFFAOYSA-N 2-ethyl-n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)butanamide Chemical compound C=1C(NC(=O)C(CC)CC)=CC=C(C=2NN=3)C=1CC=2C=3C1=CC=CC=C1 GVQMFFMYOWZTFS-UHFFFAOYSA-N 0.000 claims description 2
• BYKQQODOBVSCIN-UHFFFAOYSA-N 2-methyl-n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)butanamide Chemical compound C=1C(NC(=O)C(C)CC)=CC=C(C=2NN=3)C=1CC=2C=3C1=CC=CC=C1 BYKQQODOBVSCIN-UHFFFAOYSA-N 0.000 claims description 2
• XCSUYRGOUFRHJM-UHFFFAOYSA-N 2-morpholin-4-ylethyl 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzoate Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1C(=O)OCCN1CCOCC1 XCSUYRGOUFRHJM-UHFFFAOYSA-N 0.000 claims description 2
• VNRJGEMERJZKLQ-UHFFFAOYSA-N 2-piperazin-1-ylacetamide Chemical compound NC(=O)CN1CCNCC1 VNRJGEMERJZKLQ-UHFFFAOYSA-N 0.000 claims description 2
• VWZKZBZRQARVBA-UHFFFAOYSA-N 3-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenol Chemical compound OC1=CC=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 VWZKZBZRQARVBA-UHFFFAOYSA-N 0.000 claims description 2
• LOTXIGRJPYJKGQ-UHFFFAOYSA-N 3-(2-chloropyridin-4-yl)-4,5-dihydro-1h-benzo[g]indazole Chemical compound C1=NC(Cl)=CC(C=2C3=C(C4=CC=CC=C4CC3)NN=2)=C1 LOTXIGRJPYJKGQ-UHFFFAOYSA-N 0.000 claims description 2
• VZDAGRVQYZZNSL-UHFFFAOYSA-N 3-(3-nitrophenyl)-1,4-dihydroindeno[1,2-c]pyrazole Chemical compound [O-][N+](=O)C1=CC=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 VZDAGRVQYZZNSL-UHFFFAOYSA-N 0.000 claims description 2
• TZXSAORFPSSAER-UHFFFAOYSA-N 3-(4-methoxyphenyl)-1h-indazole Chemical compound C1=CC(OC)=CC=C1C1=NNC2=CC=CC=C12 TZXSAORFPSSAER-UHFFFAOYSA-N 0.000 claims description 2
• SHZVNCPQDAOVAD-UHFFFAOYSA-N 3-(4-nitrophenyl)-1,4-dihydroindeno[1,2-c]pyrazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NNC2=C1CC1=CC=CC=C21 SHZVNCPQDAOVAD-UHFFFAOYSA-N 0.000 claims description 2
• QADSAGPXCYCHRZ-UHFFFAOYSA-N 3-(4-phenylmethoxyphenyl)-4,5-dihydro-1h-benzo[g]indazole Chemical compound C=1C=C(C2=C3C(C4=CC=CC=C4CC3)=NN2)C=CC=1OCC1=CC=CC=C1 QADSAGPXCYCHRZ-UHFFFAOYSA-N 0.000 claims description 2
• NXWJNIXJIPXDIU-UHFFFAOYSA-N 3-(dibenzylamino)propyl n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]carbamate Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)OCCCN(CC=1C=CC=CC=1)CC1=CC=CC=C1 NXWJNIXJIPXDIU-UHFFFAOYSA-N 0.000 claims description 2
• UDTGSUIDDXQTFQ-UHFFFAOYSA-N 3-naphthalen-2-yl-1,4-dihydroindeno[1,2-c]pyrazole Chemical compound C1=CC=CC2=CC(C3=NNC=4C5=CC=CC=C5CC3=4)=CC=C21 UDTGSUIDDXQTFQ-UHFFFAOYSA-N 0.000 claims description 2
• FZSXAZUWYSBXKB-UHFFFAOYSA-N 3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine Chemical compound C=1C(N)=CC=C2C=1CC1=C2NN=C1C1=CC=CC=C1 FZSXAZUWYSBXKB-UHFFFAOYSA-N 0.000 claims description 2
• LZWDKKXPTOSMNY-UHFFFAOYSA-N 3-phenyl-1,4-dihydropyrazolo[4,3-b]indole Chemical compound C1=CC=CC=C1C1=NNC2=C1NC1=CC=CC=C12 LZWDKKXPTOSMNY-UHFFFAOYSA-N 0.000 claims description 2
• DEQJKZRYMLWJBH-UHFFFAOYSA-N 3-phenyl-1h-[1]benzothiolo[3,2-c]pyrazole Chemical compound C1=CC=CC=C1C1=NNC2=C1SC1=CC=CC=C12 DEQJKZRYMLWJBH-UHFFFAOYSA-N 0.000 claims description 2
• GHKBVHUCULFLEV-UHFFFAOYSA-N 3-phenyl-1h-[1]benzothiolo[3,2-c]pyrazole 4,4-dioxide Chemical compound C1=2S(=O)(=O)C3=CC=CC=C3C=2NN=C1C1=CC=CC=C1 GHKBVHUCULFLEV-UHFFFAOYSA-N 0.000 claims description 2
• VPUQBBLZVVYKOU-UHFFFAOYSA-N 3-phenyl-1h-[1]benzothiolo[3,2-c]pyrazole 4-oxide Chemical compound C1=2S(=O)C3=CC=CC=C3C=2NN=C1C1=CC=CC=C1 VPUQBBLZVVYKOU-UHFFFAOYSA-N 0.000 claims description 2
• OHKXFOMKYVWICK-UHFFFAOYSA-N 3-thiophen-2-yl-2,4-dihydroindeno[1,2-c]pyrazol-6-ol Chemical compound C=1C(O)=CC=C(C=2NN=3)C=1CC=2C=3C1=CC=CS1 OHKXFOMKYVWICK-UHFFFAOYSA-N 0.000 claims description 2
• MIEAJNNLTOPXHY-UHFFFAOYSA-N 3-thiophen-2-yl-2,4-dihydroindeno[1,2-c]pyrazole-6-carboxamide Chemical compound C=1C(C(=O)N)=CC=C(C=2NN=3)C=1CC=2C=3C1=CC=CS1 MIEAJNNLTOPXHY-UHFFFAOYSA-N 0.000 claims description 2
• DFGMFLAAYIKHSQ-UHFFFAOYSA-N 4,4-dimethyl-3-phenyl-1h-indeno[1,2-c]pyrazole Chemical compound C1=2C(C)(C)C3=CC=CC=C3C=2NN=C1C1=CC=CC=C1 DFGMFLAAYIKHSQ-UHFFFAOYSA-N 0.000 claims description 2
• PWWQUOQBRCDWRV-UHFFFAOYSA-N 4,4-dimethyl-n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)pentanamide Chemical compound C=1C(NC(=O)CCC(C)(C)C)=CC=C(C=2NN=3)C=1CC=2C=3C1=CC=CC=C1 PWWQUOQBRCDWRV-UHFFFAOYSA-N 0.000 claims description 2
• DKCUFNGEPZFLAL-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N'-hydroxybenzenecarboximidamide Chemical compound C1=CC(C(=NO)N)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 DKCUFNGEPZFLAL-UHFFFAOYSA-N 0.000 claims description 2
• GCDQDQZAIJGEMV-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-n-(2-piperidin-1-ylethyl)aniline Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NCCN1CCCCC1 GCDQDQZAIJGEMV-UHFFFAOYSA-N 0.000 claims description 2
• LXHUVALNZGCKKP-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-n-(2-piperidin-1-ylpropyl)aniline Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NCC(C)N1CCCCC1 LXHUVALNZGCKKP-UHFFFAOYSA-N 0.000 claims description 2
• SAHXOAMPIVSHLU-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-n-phenylbenzamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1C(=O)NC1=CC=CC=C1 SAHXOAMPIVSHLU-UHFFFAOYSA-N 0.000 claims description 2
• UXFVMXPDJJRVSD-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 UXFVMXPDJJRVSD-UHFFFAOYSA-N 0.000 claims description 2
• DMCGMQHQSQQRKJ-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 DMCGMQHQSQQRKJ-UHFFFAOYSA-N 0.000 claims description 2
• RESWJWDYENPSTN-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 RESWJWDYENPSTN-UHFFFAOYSA-N 0.000 claims description 2
• QWTVRSJRAGKCDI-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 QWTVRSJRAGKCDI-UHFFFAOYSA-N 0.000 claims description 2
• OWDFVEFSQJYENJ-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 OWDFVEFSQJYENJ-UHFFFAOYSA-N 0.000 claims description 2
• YBTINWNGIMPRDU-UHFFFAOYSA-N 4-(1H-[1]benzothiolo[3,2-c]pyrazol-3-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=NNC2=C1SC1=CC=CC=C12 YBTINWNGIMPRDU-UHFFFAOYSA-N 0.000 claims description 2
• JZPHQEGFPGOVIP-UHFFFAOYSA-N 4-(1h-[1]benzothiolo[3,2-c]pyrazol-3-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NNC2=C1SC1=CC=CC=C12 JZPHQEGFPGOVIP-UHFFFAOYSA-N 0.000 claims description 2
• CQMIUAYIGHQGPM-UHFFFAOYSA-N 4-(4,5-dihydro-1h-benzo[g]indazol-3-yl)pyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC(C=2C3=C(C4=CC=CC=C4CC3)NN=2)=C1 CQMIUAYIGHQGPM-UHFFFAOYSA-N 0.000 claims description 2
• CZIBQWUHWVSDBA-UHFFFAOYSA-N 4-[3-[3-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenoxy]propyl]morpholine Chemical compound C=1C=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=CC=1OCCCN1CCOCC1 CZIBQWUHWVSDBA-UHFFFAOYSA-N 0.000 claims description 2
• IDIZUOIZDINIKU-UHFFFAOYSA-N 4-methyl-3-phenyl-1h-indeno[1,2-c]pyrazol-4-ol Chemical compound C1=2C(C)(O)C3=CC=CC=C3C=2NN=C1C1=CC=CC=C1 IDIZUOIZDINIKU-UHFFFAOYSA-N 0.000 claims description 2
• OXZRMVCOHZYWMD-UHFFFAOYSA-N 6,7-dimethoxy-3-(3-phenoxyphenyl)-1,4-dihydroindeno[1,2-c]pyrazole Chemical compound C1=2C=C(OC)C(OC)=CC=2CC2=C1NN=C2C(C=1)=CC=CC=1OC1=CC=CC=C1 OXZRMVCOHZYWMD-UHFFFAOYSA-N 0.000 claims description 2
• FJMSOTKALQGPMI-UHFFFAOYSA-N 7-methoxy-3-(4-methylsulfonylphenyl)-4,5-dihydro-1h-benzo[g]indazole Chemical compound C=12CCC3=CC(OC)=CC=C3C2=NNC=1C1=CC=C(S(C)(=O)=O)C=C1 FJMSOTKALQGPMI-UHFFFAOYSA-N 0.000 claims description 2
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
• FRGSQAQLTAUCBF-UHFFFAOYSA-N C1=2C(=NO)C3=CC=CC=C3C=2NN=C1C1=CC=CC=C1 Chemical compound C1=2C(=NO)C3=CC=CC=C3C=2NN=C1C1=CC=CC=C1 FRGSQAQLTAUCBF-UHFFFAOYSA-N 0.000 claims description 2
• IPBUGQZTDWFCCT-UHFFFAOYSA-N C1=C[N+]([O-])=CC=C1C1=NNC2=C1CCC1=CC=CC=C21 Chemical compound C1=C[N+]([O-])=CC=C1C1=NNC2=C1CCC1=CC=CC=C21 IPBUGQZTDWFCCT-UHFFFAOYSA-N 0.000 claims description 2
• 208000003732 Cat-scratch disease Diseases 0.000 claims description 2
• 206010018498 Goitre Diseases 0.000 claims description 2
• MSMWQUJIBAYUSJ-UHFFFAOYSA-N N-[(2,5-difluorophenyl)methyl]-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine Chemical compound FC1=CC=C(F)C(CNC=2C=C3C(C=4NN=C(C=4C3)C=3C=CC=CC=3)=CC=2)=C1 MSMWQUJIBAYUSJ-UHFFFAOYSA-N 0.000 claims description 2
• AQCDOEPFYVVJGQ-UHFFFAOYSA-N N-[(2-fluorophenyl)methyl]-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine Chemical compound FC1=CC=CC=C1CNC1=CC=C2C(NN=C3C=4C=CC=CC=4)=C3CC2=C1 AQCDOEPFYVVJGQ-UHFFFAOYSA-N 0.000 claims description 2
• BAMTXAMCUSAABP-UHFFFAOYSA-N N-[(3-fluorophenyl)methyl]-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine Chemical compound FC1=CC=CC(CNC=2C=C3C(C=4NN=C(C=4C3)C=3C=CC=CC=3)=CC=2)=C1 BAMTXAMCUSAABP-UHFFFAOYSA-N 0.000 claims description 2
• FIEADPIVKAAGTA-UHFFFAOYSA-N N-[(3-nitrophenyl)methyl]-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine Chemical compound [O-][N+](=O)C1=CC=CC(CNC=2C=C3C(C4=C(C(=NN4)C=4C=CC=CC=4)C3)=CC=2)=C1 FIEADPIVKAAGTA-UHFFFAOYSA-N 0.000 claims description 2
• 208000037062 Polyps Diseases 0.000 claims description 2
• AOMILPABJUGSOD-UHFFFAOYSA-N [4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=C(CC=2C3=CC=CC=2)C3=NN1 AOMILPABJUGSOD-UHFFFAOYSA-N 0.000 claims description 2
• 125000004414 alkyl thio group Chemical group 0.000 claims description 2
• 125000000304 alkynyl group Chemical group 0.000 claims description 2
• 230000009285 allergic inflammation Effects 0.000 claims description 2
• 230000007882 cirrhosis Effects 0.000 claims description 2
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
• 208000031513 cyst Diseases 0.000 claims description 2
• 150000002148 esters Chemical class 0.000 claims description 2
• DOMDPVJKTBOZGZ-UHFFFAOYSA-N ethyl 2-[3-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenoxy]acetate Chemical compound CCOC(=O)COC1=CC=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 DOMDPVJKTBOZGZ-UHFFFAOYSA-N 0.000 claims description 2
• 201000011066 hemangioma Diseases 0.000 claims description 2
• 230000000302 ischemic effect Effects 0.000 claims description 2
• 230000002107 myocardial effect Effects 0.000 claims description 2
• VAFLKVSPFIXPNY-UHFFFAOYSA-N n-(2-bromoethyl)-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound C1=CC(C(=O)NCCBr)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 VAFLKVSPFIXPNY-UHFFFAOYSA-N 0.000 claims description 2
• SLQXSGJKXLBPDJ-UHFFFAOYSA-N n-(2-chloroethyl)-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound C1=CC(C(=O)NCCCl)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 SLQXSGJKXLBPDJ-UHFFFAOYSA-N 0.000 claims description 2
• WHAFGTFNZYCDFH-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C(C=2NN=C(C=2C2)C=3C=CC=CC=3)C2=CC=1NCCN1CCOCC1 WHAFGTFNZYCDFH-UHFFFAOYSA-N 0.000 claims description 2
• WYUIMDPWKPBPEQ-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole-6-carboxamide Chemical compound C=1C=C(C=2NN=C(C=2C2)C=3C=CC=CC=3)C2=CC=1C(=O)NCCN1CCOCC1 WYUIMDPWKPBPEQ-UHFFFAOYSA-N 0.000 claims description 2
• NOZYHRHPAFRQNK-UHFFFAOYSA-N n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)-2-piperidin-1-ylacetamide Chemical compound C=1C=C(C=2NN=C(C=2C2)C=3C=CC=CC=3)C2=CC=1NC(=O)CN1CCCCC1 NOZYHRHPAFRQNK-UHFFFAOYSA-N 0.000 claims description 2
• IGMIUKIYAIZUNH-UHFFFAOYSA-N n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)-2-thiomorpholin-4-ylacetamide Chemical compound C=1C=C(C=2NN=C(C=2C2)C=3C=CC=CC=3)C2=CC=1NC(=O)CN1CCSCC1 IGMIUKIYAIZUNH-UHFFFAOYSA-N 0.000 claims description 2
• KMAKSKZXPGWWMW-UHFFFAOYSA-N n-(cyclohexylmethyl)-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1C(=O)NCC1CCCCC1 KMAKSKZXPGWWMW-UHFFFAOYSA-N 0.000 claims description 2
• ZURBZKMYIOVOGJ-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1C(=O)NCC1CC1 ZURBZKMYIOVOGJ-UHFFFAOYSA-N 0.000 claims description 2
• OLBCBJLTUPNFPS-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound C1=CC(C(=O)NCCN(CC)CC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 OLBCBJLTUPNFPS-UHFFFAOYSA-N 0.000 claims description 2
• WFWLZZLWSJSYLR-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-2-piperazin-1-ylacetamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)CN1CCNCC1 WFWLZZLWSJSYLR-UHFFFAOYSA-N 0.000 claims description 2
• BTLUJCIEGRUNHB-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-2-piperidin-1-ylacetamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)CN1CCCCC1 BTLUJCIEGRUNHB-UHFFFAOYSA-N 0.000 claims description 2
• JNRWWZAEBPCXGQ-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-4-(4-hydroxyphenyl)piperazine-1-carboxamide Chemical compound C1=CC(O)=CC=C1N1CCN(C(=O)NC=2C=CC(=CC=2)C=2C3=C(C4=CC=CC=C4C3)NN=2)CC1 JNRWWZAEBPCXGQ-UHFFFAOYSA-N 0.000 claims description 2
• MZKPBSSNSUFLPK-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-4-pyridin-2-ylpiperazine-1-carboxamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)N(CC1)CCN1C1=CC=CC=N1 MZKPBSSNSUFLPK-UHFFFAOYSA-N 0.000 claims description 2
• MLGIYWYBDDCOSJ-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-n',n'-diethylethane-1,2-diamine Chemical compound C1=CC(NCCN(CC)CC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 MLGIYWYBDDCOSJ-UHFFFAOYSA-N 0.000 claims description 2
• OACZBORYQQPYTE-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]benzamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)C1=CC=CC=C1 OACZBORYQQPYTE-UHFFFAOYSA-N 0.000 claims description 2
• BEYSNIPDUYZVTO-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]benzenesulfonamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NS(=O)(=O)C1=CC=CC=C1 BEYSNIPDUYZVTO-UHFFFAOYSA-N 0.000 claims description 2
• BZMPJVWWJKMGNW-UHFFFAOYSA-N n-[4-(1-acetyl-4h-indeno[1,2-c]pyrazol-3-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NN(C(C)=O)C2=C1CC1=CC=CC=C21 BZMPJVWWJKMGNW-UHFFFAOYSA-N 0.000 claims description 2
• VEIGCGRVZQDIKE-UHFFFAOYSA-N n-[4-(4,5-dihydro-1h-benzo[g]indazol-3-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=C(CCC=2C3=CC=CC=2)C3=NN1 VEIGCGRVZQDIKE-UHFFFAOYSA-N 0.000 claims description 2
• YOANQLJKXOJLIJ-UHFFFAOYSA-N n-cyclopentyl-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1C(=O)NC1CCCC1 YOANQLJKXOJLIJ-UHFFFAOYSA-N 0.000 claims description 2
• MVUYXVYNVSQAOS-UHFFFAOYSA-N n-methyl-3-thiophen-2-yl-2,4-dihydroindeno[1,2-c]pyrazole-6-carboxamide Chemical compound C=1C(C(=O)NC)=CC=C(C=2NN=3)C=1CC=2C=3C1=CC=CS1 MVUYXVYNVSQAOS-UHFFFAOYSA-N 0.000 claims description 2
• BIKGIKNTIRBXJC-UHFFFAOYSA-N n-phenyl-3-thiophen-2-yl-2,4-dihydroindeno[1,2-c]pyrazole-6-carboxamide Chemical compound C=1C=C(C=2NN=C(C=2C2)C=3SC=CC=3)C2=CC=1C(=O)NC1=CC=CC=C1 BIKGIKNTIRBXJC-UHFFFAOYSA-N 0.000 claims description 2
• GSWQACIMNXIUKQ-UHFFFAOYSA-N n-phenyl-n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)benzamide Chemical compound C=1C=CC=CC=1C(=O)N(C=1C=C2C(C3=C(C(=NN3)C=3C=CC=CC=3)C2)=CC=1)C1=CC=CC=C1 GSWQACIMNXIUKQ-UHFFFAOYSA-N 0.000 claims description 2
• LBERCSNDUQGYLI-UHFFFAOYSA-N n-tert-butyl-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 LBERCSNDUQGYLI-UHFFFAOYSA-N 0.000 claims description 2
• 230000002685 pulmonary effect Effects 0.000 claims description 2
• 201000004595 synovitis Diseases 0.000 claims description 2
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 8
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 6
• 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 5
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 4
• 125000003282 alkyl amino group Chemical group 0.000 claims 4
• 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 4
• 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
• 125000004802 cyanophenyl group Chemical group 0.000 claims 2
• 125000002757 morpholinyl group Chemical group 0.000 claims 2
• LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 claims 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
• HIOBYGWOPSIHOJ-UHFFFAOYSA-N 1,1-bis[2-(diethylamino)ethyl]-3-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]urea Chemical compound C1=CC(NC(=O)N(CCN(CC)CC)CCN(CC)CC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 HIOBYGWOPSIHOJ-UHFFFAOYSA-N 0.000 claims 1
• PSLSIRTWJWVDMC-UHFFFAOYSA-N 1-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-3-[(1-ethylpyrrolidin-2-yl)methyl]urea Chemical compound CCN1CCCC1CNC(=O)NC1=CC=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=C1 PSLSIRTWJWVDMC-UHFFFAOYSA-N 0.000 claims 1
• OXGZSDKRIGQETO-UHFFFAOYSA-N 1-benzyl-3-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-1-methylurea Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)N(C)CC1=CC=CC=C1 OXGZSDKRIGQETO-UHFFFAOYSA-N 0.000 claims 1
• XHBMHGFKYIGCNJ-UHFFFAOYSA-N 2-(diethylamino)ethyl n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]carbamate Chemical compound C1=CC(NC(=O)OCCN(CC)CC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 XHBMHGFKYIGCNJ-UHFFFAOYSA-N 0.000 claims 1
• LZDQPXAJNKGROO-UHFFFAOYSA-N 2-(dimethylamino)-n-phenylacetamide Chemical compound CN(C)CC(=O)NC1=CC=CC=C1 LZDQPXAJNKGROO-UHFFFAOYSA-N 0.000 claims 1
• JPULUQHTUYCRCO-UHFFFAOYSA-N 2-amino-2-ethyl-n-phenylbutanamide Chemical compound CCC(N)(CC)C(=O)NC1=CC=CC=C1 JPULUQHTUYCRCO-UHFFFAOYSA-N 0.000 claims 1
• WZQIDOJLPGDHKR-UHFFFAOYSA-N 2-methyl-n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)propanamide Chemical compound C=1C(NC(=O)C(C)C)=CC=C(C=2NN=3)C=1CC=2C=3C1=CC=CC=C1 WZQIDOJLPGDHKR-UHFFFAOYSA-N 0.000 claims 1
• BWRNWWSQZROEOA-UHFFFAOYSA-N 2-morpholin-4-ylacetamide Chemical compound NC(=O)CN1CCOCC1 BWRNWWSQZROEOA-UHFFFAOYSA-N 0.000 claims 1
• AQLMEDWBRMLKMT-UHFFFAOYSA-N 3-(3,4,5-trimethoxyphenyl)-1,4-dihydroindeno[1,2-c]pyrazole Chemical compound COC1=C(OC)C(OC)=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 AQLMEDWBRMLKMT-UHFFFAOYSA-N 0.000 claims 1
• BUFKHTUFIAELAF-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-n-[2-(4-methylpiperazin-1-yl)ethyl]aniline Chemical compound C1CN(C)CCN1CCNC1=CC=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=C1 BUFKHTUFIAELAF-UHFFFAOYSA-N 0.000 claims 1
• YWKCCNUJIMSBNZ-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-n-[2-(4-methylpiperazin-1-yl)propyl]aniline Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NCC(C)N1CCN(C)CC1 YWKCCNUJIMSBNZ-UHFFFAOYSA-N 0.000 claims 1
• MAPZIEVIPSNCMK-UHFFFAOYSA-N 4-(4,5-dihydro-1h-benzo[g]indazol-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC(C=2C3=C(C4=CC=CC=C4CC3)NN=2)=C1 MAPZIEVIPSNCMK-UHFFFAOYSA-N 0.000 claims 1
• KJTRXVXWSSPHRV-UHFFFAOYSA-N 4-benzoyl-5-methyl-2-phenyl-1h-pyrazol-3-one Chemical compound O=C1C(C(=O)C=2C=CC=CC=2)=C(C)NN1C1=CC=CC=C1 KJTRXVXWSSPHRV-UHFFFAOYSA-N 0.000 claims 1
• IQSFPKGCKCBZCI-UHFFFAOYSA-N 5-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N-[2-(dimethylamino)ethyl]-2-hydroxybenzamide Chemical compound C1=C(O)C(C(=O)NCCN(C)C)=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 IQSFPKGCKCBZCI-UHFFFAOYSA-N 0.000 claims 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 1
• 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
• 206010017076 Fracture Diseases 0.000 claims 1
• 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims 1
• 208000002260 Keloid Diseases 0.000 claims 1
• 206010023330 Keloid scar Diseases 0.000 claims 1
• 241001024304 Mino Species 0.000 claims 1
• AUKHUAPEHCEOSA-UHFFFAOYSA-N N-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound O=C(Nc1n[nH]c-2c1Cc1ccccc-21)c1ccccc1 AUKHUAPEHCEOSA-UHFFFAOYSA-N 0.000 claims 1
• AIAWVXNEIHSMAZ-UHFFFAOYSA-N N-[2-(1,4-diazepan-1-yl)ethyl]-5-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-2-hydroxybenzamide Chemical compound OC1=CC=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=C1C(=O)NCCN1CCCNCC1 AIAWVXNEIHSMAZ-UHFFFAOYSA-N 0.000 claims 1
• IUDDUKLQFYYZHK-UHFFFAOYSA-N N-[3-(diethylamino)propyl]-5-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-2-hydroxybenzamide Chemical compound C1=C(O)C(C(=O)NCCCN(CC)CC)=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 IUDDUKLQFYYZHK-UHFFFAOYSA-N 0.000 claims 1
• CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
• 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
• 125000005189 alkyl hydroxy group Chemical group 0.000 claims 1
• WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 1
• 235000019270 ammonium chloride Nutrition 0.000 claims 1
• 230000000259 anti-tumor effect Effects 0.000 claims 1
• DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
• 208000021921 corneal disease Diseases 0.000 claims 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
• 230000035558 fertility Effects 0.000 claims 1
• ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
• 210000001117 keloid Anatomy 0.000 claims 1
• BOEFZJVMKADQEH-UHFFFAOYSA-N methyl 4-(6-acetamido-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=NNC2=C1CC1=CC(NC(C)=O)=CC=C21 BOEFZJVMKADQEH-UHFFFAOYSA-N 0.000 claims 1
• 150000004702 methyl esters Chemical class 0.000 claims 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
• BZJWOKWRQPUASY-UHFFFAOYSA-N n-(2,2-difluoroethyl)-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzamide Chemical compound C1=CC(C(=O)NCC(F)F)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 BZJWOKWRQPUASY-UHFFFAOYSA-N 0.000 claims 1
• UWRFXFMRZNCYAM-UHFFFAOYSA-N n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)-2-pyrrolidin-1-ylacetamide Chemical compound C=1C=C(C=2NN=C(C=2C2)C=3C=CC=CC=3)C2=CC=1NC(=O)CN1CCCC1 UWRFXFMRZNCYAM-UHFFFAOYSA-N 0.000 claims 1
• IWMJAJCIPRRUBW-UHFFFAOYSA-N n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(C=1)=CC=C2C=1CC1=C2NN=C1C1=CC=CC=C1 IWMJAJCIPRRUBW-UHFFFAOYSA-N 0.000 claims 1
• ZCRVGKPHBXEZHE-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-4-(4-fluorophenyl)piperazine-1-carboxamide Chemical compound C1=CC(F)=CC=C1N1CCN(C(=O)NC=2C=CC(=CC=2)C=2C3=C(C4=CC=CC=C4C3)NN=2)CC1 ZCRVGKPHBXEZHE-UHFFFAOYSA-N 0.000 claims 1
• JFLNMUHMRZEGOD-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 JFLNMUHMRZEGOD-UHFFFAOYSA-N 0.000 claims 1
• FPYGHAQWLPMSAZ-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]piperidine-1-carboxamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)N1CCCCC1 FPYGHAQWLPMSAZ-UHFFFAOYSA-N 0.000 claims 1
• 125000006501 nitrophenyl group Chemical group 0.000 claims 1
• IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims 1
• 230000035935 pregnancy Effects 0.000 claims 1
• 125000003944 tolyl group Chemical group 0.000 claims 1
• 230000036269 ulceration Effects 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 abstract description 17
• 230000008569 process Effects 0.000 abstract description 13
• 230000004927 fusion Effects 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 45
• 239000000203 mixture Substances 0.000 description 44
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 34
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
• 238000006243 chemical reaction Methods 0.000 description 26
• 102000005962 receptors Human genes 0.000 description 25
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 24
• 108020003175 receptors Proteins 0.000 description 23
• 108090000623 proteins and genes Proteins 0.000 description 22
• 102000004169 proteins and genes Human genes 0.000 description 22
• 235000018102 proteins Nutrition 0.000 description 21
• 229940088598 enzyme Drugs 0.000 description 20
• 238000011282 treatment Methods 0.000 description 20
• 239000003446 ligand Substances 0.000 description 19
• 239000000243 solution Substances 0.000 description 18
• 239000000546 pharmaceutical excipient Substances 0.000 description 17
• 239000000758 substrate Substances 0.000 description 17
• 241000282414 Homo sapiens Species 0.000 description 16
• 241000699670 Mus sp. Species 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
• 239000003795 chemical substances by application Substances 0.000 description 15
• 239000012442 inert solvent Substances 0.000 description 14
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 13
• 239000000872 buffer Substances 0.000 description 13
• 238000006366 phosphorylation reaction Methods 0.000 description 13
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
• 238000002965 ELISA Methods 0.000 description 11
• 230000001404 mediated effect Effects 0.000 description 11
• 230000026731 phosphorylation Effects 0.000 description 11
• 230000004044 response Effects 0.000 description 11
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 10
• 230000002491 angiogenic effect Effects 0.000 description 10
• 230000001413 cellular effect Effects 0.000 description 10
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
• 239000002953 phosphate buffered saline Substances 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 9
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 8
• 206010029113 Neovascularisation Diseases 0.000 description 8
• 210000001744 T-lymphocyte Anatomy 0.000 description 8
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 8
• 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 8
• 210000002889 endothelial cell Anatomy 0.000 description 8
• 230000014509 gene expression Effects 0.000 description 8
• 239000003102 growth factor Substances 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 230000035755 proliferation Effects 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 241000701447 unidentified baculovirus Species 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 7
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
• 241001465754 Metazoa Species 0.000 description 7
• 101100481410 Mus musculus Tek gene Proteins 0.000 description 7
• 102000003923 Protein Kinase C Human genes 0.000 description 7
• 108090000315 Protein Kinase C Proteins 0.000 description 7
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 7
• 230000006044 T cell activation Effects 0.000 description 7
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
• 150000001413 amino acids Chemical group 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 239000006184 cosolvent Substances 0.000 description 7
• 230000003834 intracellular effect Effects 0.000 description 7
• 239000002773 nucleotide Substances 0.000 description 7
• 125000003729 nucleotide group Chemical group 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 7
• 210000003556 vascular endothelial cell Anatomy 0.000 description 7
• 101100481408 Danio rerio tie2 gene Proteins 0.000 description 6
• 206010015866 Extravasation Diseases 0.000 description 6
• 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 6
• 108700020796 Oncogene Proteins 0.000 description 6
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
• 108091008605 VEGF receptors Proteins 0.000 description 6
• 230000003213 activating effect Effects 0.000 description 6
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 210000004204 blood vessel Anatomy 0.000 description 6
• 229940098773 bovine serum albumin Drugs 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 230000004663 cell proliferation Effects 0.000 description 6
• 230000008021 deposition Effects 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 230000003511 endothelial effect Effects 0.000 description 6
• 230000036251 extravasation Effects 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 238000002649 immunization Methods 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
• 230000002062 proliferating effect Effects 0.000 description 6
• 230000019491 signal transduction Effects 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 238000013268 sustained release Methods 0.000 description 6
• 239000012730 sustained-release form Substances 0.000 description 6
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 6
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 108010002350 Interleukin-2 Proteins 0.000 description 5
• 102000000588 Interleukin-2 Human genes 0.000 description 5
• 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 5
• 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 5
• 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 5
• 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 5
• 230000000903 blocking effect Effects 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229940014259 gelatin Drugs 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 238000010438 heat treatment Methods 0.000 description 5
• 230000002209 hydrophobic effect Effects 0.000 description 5
• 230000003463 hyperproliferative effect Effects 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 230000008728 vascular permeability Effects 0.000 description 5
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 208000009386 Experimental Arthritis Diseases 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
• 102100035194 Placenta growth factor Human genes 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
• 229960000583 acetic acid Drugs 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 235000001014 amino acid Nutrition 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 235000013877 carbamide Nutrition 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 230000033077 cellular process Effects 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
• 210000000416 exudates and transudate Anatomy 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 239000008177 pharmaceutical agent Substances 0.000 description 4
• 230000036470 plasma concentration Effects 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
• 101150012716 CDK1 gene Proteins 0.000 description 3
• 208000005623 Carcinogenesis Diseases 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 3
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
• 108010074328 Interferon-gamma Proteins 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
• 208000001344 Macular Edema Diseases 0.000 description 3
• 206010025415 Macular oedema Diseases 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 239000013504 Triton X-100 Substances 0.000 description 3
• 229920004890 Triton X-100 Polymers 0.000 description 3
• 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 3
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 3
• 235000011054 acetic acid Nutrition 0.000 description 3
• 206010064930 age-related macular degeneration Diseases 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 230000036952 cancer formation Effects 0.000 description 3
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
• 231100000504 carcinogenesis Toxicity 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 238000002425 crystallisation Methods 0.000 description 3
• 230000008025 crystallization Effects 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 201000002491 encephalomyelitis Diseases 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 229940011871 estrogen Drugs 0.000 description 3
• 239000000262 estrogen Substances 0.000 description 3
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
• 210000002744 extracellular matrix Anatomy 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 239000007943 implant Substances 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 230000031146 intracellular signal transduction Effects 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
• 108010052968 leupeptin Proteins 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 238000004811 liquid chromatography Methods 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 201000010230 macular retinal edema Diseases 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 230000001613 neoplastic effect Effects 0.000 description 3
• 231100000590 oncogenic Toxicity 0.000 description 3
• 230000002246 oncogenic effect Effects 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000000825 pharmaceutical preparation Substances 0.000 description 3
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 230000000770 proinflammatory effect Effects 0.000 description 3
• 239000011535 reaction buffer Substances 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 210000004291 uterus Anatomy 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 2
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
• 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 206010051392 Diapedesis Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 101150048336 Flt1 gene Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
• 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 208000001953 Hypotension Diseases 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• 102100037850 Interferon gamma Human genes 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 206010025538 Malignant ascites Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 101150024075 Mapk1 gene Proteins 0.000 description 2
• UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 2
• KACHFMOHOPLTNX-UHFFFAOYSA-N Methyl EudesMate Chemical compound COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 KACHFMOHOPLTNX-UHFFFAOYSA-N 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 102100028762 Neuropilin-1 Human genes 0.000 description 2
• 108090000772 Neuropilin-1 Proteins 0.000 description 2
• 208000010191 Osteitis Deformans Diseases 0.000 description 2
• 101150093908 PDGFRB gene Proteins 0.000 description 2
• 208000027868 Paget disease Diseases 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 208000005228 Pericardial Effusion Diseases 0.000 description 2
• 208000002151 Pleural effusion Diseases 0.000 description 2
• 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 108050003452 SH2 domains Proteins 0.000 description 2
• 102000014400 SH2 domains Human genes 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 2
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 238000001261 affinity purification Methods 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 229940040563 agaric acid Drugs 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• 238000009835 boiling Methods 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 208000001969 capillary hemangioma Diseases 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 150000001733 carboxylic acid esters Chemical group 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 238000012761 co-transfection Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000005520 cutting process Methods 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• 229960005309 estradiol Drugs 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 238000001125 extrusion Methods 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 238000001030 gas--liquid chromatography Methods 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 238000000227 grinding Methods 0.000 description 2
• 230000009033 hematopoietic malignancy Effects 0.000 description 2
• 238000005734 heterodimerization reaction Methods 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
• 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
• 150000007857 hydrazones Chemical class 0.000 description 2
• 230000036543 hypotension Effects 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 230000001965 increasing effect Effects 0.000 description 2
• QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 230000004073 interleukin-2 production Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• 238000000021 kinase assay Methods 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 208000027202 mammary Paget disease Diseases 0.000 description 2
• 108010082117 matrigel Proteins 0.000 description 2
• 235000010755 mineral Nutrition 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• 230000002297 mitogenic effect Effects 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 230000035699 permeability Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
• 229940080469 phosphocellulose Drugs 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
• 230000006884 regulation of angiogenesis Effects 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 125000005504 styryl group Chemical group 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 239000011975 tartaric acid Substances 0.000 description 2
• 235000002906 tartaric acid Nutrition 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 239000012096 transfection reagent Substances 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
• 230000006459 vascular development Effects 0.000 description 2
• 230000006711 vascular endothelial growth factor production Effects 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• DXOFMKNITCKTIS-QXMHVHEDSA-N (z)-2-ethyloctadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCC(CC)C(O)=O DXOFMKNITCKTIS-QXMHVHEDSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• JRTSIRSYIGGHSA-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-ylmethyl)-3-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]urea Chemical compound C1C2=CC=CC=C2C2=C1C(C1=CC=C(C=C1)NC(NCC=1C=C3OCOC3=CC=1)=O)=NN2 JRTSIRSYIGGHSA-UHFFFAOYSA-N 0.000 description 1
• YDXMAHZQXGADLW-UHFFFAOYSA-N 1-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-3-(1,3-dihydroxypropan-2-yl)urea Chemical compound C1=CC(NC(=O)NC(CO)CO)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 YDXMAHZQXGADLW-UHFFFAOYSA-N 0.000 description 1
• RKAHCSLHLVDMRE-UHFFFAOYSA-N 1-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-3-(2,3-dihydroxypropyl)urea Chemical compound C1=CC(NC(=O)NCC(O)CO)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 RKAHCSLHLVDMRE-UHFFFAOYSA-N 0.000 description 1
• OJDVDPRBUUHOCJ-UHFFFAOYSA-N 1-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-3-(2-thiophen-2-ylethyl)urea Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)NCCC1=CC=CS1 OJDVDPRBUUHOCJ-UHFFFAOYSA-N 0.000 description 1
• LGSINGCFEQYZKR-UHFFFAOYSA-N 1-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-3-(furan-2-ylmethyl)urea Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)NCC1=CC=CO1 LGSINGCFEQYZKR-UHFFFAOYSA-N 0.000 description 1
• XOJWWWDQBNPVJS-UHFFFAOYSA-N 1-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-3-[2-(2-hydroxyethoxy)ethyl]urea Chemical compound C1=CC(NC(=O)NCCOCCO)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 XOJWWWDQBNPVJS-UHFFFAOYSA-N 0.000 description 1
• HCUQTLBYRLHUPO-UHFFFAOYSA-N 1-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-3-[7-(dimethylamino)heptyl]urea Chemical compound C1=CC(NC(=O)NCCCCCCCN(C)C)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 HCUQTLBYRLHUPO-UHFFFAOYSA-N 0.000 description 1
• FZDHIUVJMXAQDR-UHFFFAOYSA-N 1-benzyl-3-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]urea Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)NCC1=CC=CC=C1 FZDHIUVJMXAQDR-UHFFFAOYSA-N 0.000 description 1
• ORIVCPWUWYTQTI-UHFFFAOYSA-N 1-cyclobutyl-3-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]urea Chemical compound C1(CCC1)NC(=O)NC1=CC=C(C=C1)C=1C2=C(NN1)C1=CC=CC=C1C2 ORIVCPWUWYTQTI-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
• ZFFYDQAURJCWPQ-UHFFFAOYSA-N 2,3-dihydroinden-1-ylidenehydrazine Chemical compound C1=CC=C2C(=NN)CCC2=C1 ZFFYDQAURJCWPQ-UHFFFAOYSA-N 0.000 description 1
• XYEBHXHJHAPEGR-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=NNC=C1 XYEBHXHJHAPEGR-UHFFFAOYSA-N 0.000 description 1
• DZPRQTSFNHFNFA-UHFFFAOYSA-N 2-(diethylamino)-n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)CN(CC)CC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 DZPRQTSFNHFNFA-UHFFFAOYSA-N 0.000 description 1
• WOWVOEVNUNJEHD-UHFFFAOYSA-N 2-[3-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 WOWVOEVNUNJEHD-UHFFFAOYSA-N 0.000 description 1
• MEZFQICOVFZJQN-UHFFFAOYSA-N 2-bromo-3-chloro-4-methylbenzenesulfonyl iodide Chemical compound ClC=1C(=C(S(=O)(=O)I)C=CC1C)Br MEZFQICOVFZJQN-UHFFFAOYSA-N 0.000 description 1
• IHCDQQHNHQCALV-UHFFFAOYSA-N 2-methoxyethylurea Chemical compound COCCNC(N)=O IHCDQQHNHQCALV-UHFFFAOYSA-N 0.000 description 1
• SGQJWUFCYNXIRZ-UHFFFAOYSA-N 2-methyl-n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)pentanamide Chemical compound C=1C(NC(=O)C(C)CCC)=CC=C(C=2NN=3)C=1CC=2C=3C1=CC=CC=C1 SGQJWUFCYNXIRZ-UHFFFAOYSA-N 0.000 description 1
• LDASZBYEGQNNHH-UHFFFAOYSA-N 3-(4-isocyanatophenyl)-1,4-dihydroindeno[1,2-c]pyrazole Chemical compound C1=CC(N=C=O)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 LDASZBYEGQNNHH-UHFFFAOYSA-N 0.000 description 1
• NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
• UVHOMHKEEYZAAE-UHFFFAOYSA-N 3-[3-[3-(4-methyl-1,4-diazepan-1-yl)propoxy]phenyl]-1,4-dihydroindeno[1,2-c]pyrazole Chemical compound C1CN(C)CCCN1CCCOC1=CC=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 UVHOMHKEEYZAAE-UHFFFAOYSA-N 0.000 description 1
• VRUCPWFREHUVQG-UHFFFAOYSA-N 3-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-1-[2-(dimethylamino)ethyl]-1-methylurea Chemical compound C1=CC(NC(=O)N(C)CCN(C)C)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 VRUCPWFREHUVQG-UHFFFAOYSA-N 0.000 description 1
• BWYHTJIIHHALIW-UHFFFAOYSA-N 3-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-1-ethyl-1-(2-hydroxyethyl)urea Chemical compound C1=CC(NC(=O)N(CCO)CC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 BWYHTJIIHHALIW-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• NHLPIZCZLHKOHE-UHFFFAOYSA-N 3-chloro-4-(2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenol Chemical compound ClC1=CC(O)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 NHLPIZCZLHKOHE-UHFFFAOYSA-N 0.000 description 1
• CAHBZOYWFVKAGQ-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 CAHBZOYWFVKAGQ-UHFFFAOYSA-N 0.000 description 1
• YMFGFGAGJSWHCL-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-n-(2-piperazin-1-ylethyl)aniline Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NCCN1CCNCC1 YMFGFGAGJSWHCL-UHFFFAOYSA-N 0.000 description 1
• GAMATGTZWPSCHP-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-n-(2-piperazin-1-ylpropyl)aniline Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NCC(C)N1CCNCC1 GAMATGTZWPSCHP-UHFFFAOYSA-N 0.000 description 1
• GRVZZDLYUPSYPY-UHFFFAOYSA-N 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-n-(4-nitrophenyl)benzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)C1=CC=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=C1 GRVZZDLYUPSYPY-UHFFFAOYSA-N 0.000 description 1
• ZJRCNSMPDDWYRZ-UHFFFAOYSA-N 4-(1h-[1]benzothiolo[3,2-c]pyrazol-3-yl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=NNC2=C1SC1=CC=CC=C12 ZJRCNSMPDDWYRZ-UHFFFAOYSA-N 0.000 description 1
• OCBKTJVYPSNJAH-UHFFFAOYSA-N 4-(4,5-dihydro-1H-benzo[g]indazol-3-yl)-N'-hydroxypyridine-2-carboximidamide Chemical compound C1=NC(C(=NO)N)=CC(C=2C3=C(C4=CC=CC=C4CC3)NN=2)=C1 OCBKTJVYPSNJAH-UHFFFAOYSA-N 0.000 description 1
• FIDNOLGYFNGSAX-UHFFFAOYSA-N 4-[2-[(3-thiophen-2-yl-2,4-dihydroindeno[1,2-c]pyrazol-6-yl)oxy]ethyl]morpholine Chemical compound C=1C=C(C=2NN=C(C=2C2)C=3SC=CC=3)C2=CC=1OCCN1CCOCC1 FIDNOLGYFNGSAX-UHFFFAOYSA-N 0.000 description 1
• NOVIMFWIBXGPFT-UHFFFAOYSA-N 4-[2-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenoxy]ethyl]morpholine Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1OCCN1CCOCC1 NOVIMFWIBXGPFT-UHFFFAOYSA-N 0.000 description 1
• JLHHAYQJKONHPV-UHFFFAOYSA-N 4-[3-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 JLHHAYQJKONHPV-UHFFFAOYSA-N 0.000 description 1
• FDSIGMNOHIDNBJ-UHFFFAOYSA-N 4-methyl-3-phenyl-1h-pyrazolo[4,3-b]indole Chemical compound C1=2N(C)C3=CC=CC=C3C=2NN=C1C1=CC=CC=C1 FDSIGMNOHIDNBJ-UHFFFAOYSA-N 0.000 description 1
• SJRWJKKXBSKELZ-UHFFFAOYSA-N 5-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-2-hydroxy-N-[3-(4-methylpiperazin-1-yl)propyl]benzamide Chemical compound C1CN(C)CCN1CCCNC(=O)C1=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=CC=C1O SJRWJKKXBSKELZ-UHFFFAOYSA-N 0.000 description 1
• SEUJBOHBOWTJEH-UHFFFAOYSA-N 5-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N-[3-[di(propan-2-yl)amino]propyl]-2-hydroxybenzamide Chemical compound C1=C(O)C(C(=O)NCCCN(C(C)C)C(C)C)=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 SEUJBOHBOWTJEH-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 241000588832 Bordetella pertussis Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000002381 Brain Hypoxia Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 108091007914 CDKs Proteins 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• RGSIACRHPDEBIQ-UHFFFAOYSA-N Cl.Cl.N1N=C(C=C1)NC1=CC=CC=C1 Chemical compound Cl.Cl.N1N=C(C=C1)NC1=CC=CC=C1 RGSIACRHPDEBIQ-UHFFFAOYSA-N 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000000503 Collagen Type II Human genes 0.000 description 1
• 108010041390 Collagen Type II Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 208000016974 Eales' disease Diseases 0.000 description 1
• 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 206010052139 Eye oedema Diseases 0.000 description 1
• 101150009958 FLT4 gene Proteins 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
• 238000004566 IR spectroscopy Methods 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
• 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
• 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 1
• 101710182491 Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 1
• 108010024121 Janus Kinases Proteins 0.000 description 1
• 102000015617 Janus Kinases Human genes 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 102100026023 LIM domain kinase 1 Human genes 0.000 description 1
• 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
• 102000047918 Myelin Basic Human genes 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• YYBGAFYVDMMSJL-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine Chemical compound FC1=CC(F)=CC=C1CNC1=CC=C2C(NN=C3C=4C=CC=CC=4)=C3CC2=C1 YYBGAFYVDMMSJL-UHFFFAOYSA-N 0.000 description 1
• VOOCRCRRNMQWPJ-UHFFFAOYSA-N N-[(3,5-difluorophenyl)methyl]-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine Chemical compound FC1=CC(F)=CC(CNC=2C=C3C(C=4NN=C(C=4C3)C=3C=CC=CC=3)=CC=2)=C1 VOOCRCRRNMQWPJ-UHFFFAOYSA-N 0.000 description 1
• YFCBROPSUBDLQM-UHFFFAOYSA-N N-[(4-fluorophenyl)methyl]-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine Chemical compound C1=CC(F)=CC=C1CNC1=CC=C2C(NN=C3C=4C=CC=CC=4)=C3CC2=C1 YFCBROPSUBDLQM-UHFFFAOYSA-N 0.000 description 1
• FSLUGVNWGSKCTC-UHFFFAOYSA-N N-[(4-nitrophenyl)methyl]-3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CNC1=CC=C2C(NN=C3C=4C=CC=CC=4)=C3CC2=C1 FSLUGVNWGSKCTC-UHFFFAOYSA-N 0.000 description 1
• DBGLURYPKYJAPY-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-5-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-2-hydroxybenzamide Chemical compound C1=C(O)C(C(=O)NCCN(CC)CC)=CC(C=2C3=C(C4=CC=CC=C4C3)NN=2)=C1 DBGLURYPKYJAPY-UHFFFAOYSA-N 0.000 description 1
• FTXYCEULXUANPM-UHFFFAOYSA-N N-[3-(1,4-diazepan-1-yl)propyl]-5-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-2-hydroxybenzamide Chemical compound OC1=CC=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=C1C(=O)NCCCN1CCCNCC1 FTXYCEULXUANPM-UHFFFAOYSA-N 0.000 description 1
• CFUGPHKEJBUZHH-UHFFFAOYSA-N N-[3-(azepan-1-yl)propyl]-5-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-2-hydroxybenzamide Chemical compound OC1=CC=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=C1C(=O)NCCCN1CCCCCC1 CFUGPHKEJBUZHH-UHFFFAOYSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• YGECPQUSEJNWBS-UHFFFAOYSA-N N1N=C(C2=C1C1=CC=CC=C1C2)C2=CC=C(NCCN(C)C)C=C2 Chemical compound N1N=C(C2=C1C1=CC=CC=C1C2)C2=CC=C(NCCN(C)C)C=C2 YGECPQUSEJNWBS-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 102000016979 Other receptors Human genes 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108010082093 Placenta Growth Factor Proteins 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 206010036049 Polycystic ovaries Diseases 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 229920002642 Polysorbate 65 Polymers 0.000 description 1
• 241001417524 Pomacanthidae Species 0.000 description 1
• 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
• 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
• 206010037075 Protozoal infections Diseases 0.000 description 1
• 239000012083 RIPA buffer Substances 0.000 description 1
• 102100022419 RPA-interacting protein Human genes 0.000 description 1
• 229940078123 Ras inhibitor Drugs 0.000 description 1
• 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
• 101000851003 Rattus norvegicus Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
• 241000220317 Rosa Species 0.000 description 1
• 102000038012 SFKs Human genes 0.000 description 1
• 108091008118 SFKs Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 108010009978 Tec protein-tyrosine kinase Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 201000005485 Toxoplasmosis Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 206010053648 Vascular occlusion Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010047663 Vitritis Diseases 0.000 description 1
• 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
• 108700025690 abl Genes Proteins 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 150000008065 acid anhydrides Chemical class 0.000 description 1
• 239000003377 acid catalyst Substances 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000012042 active reagent Substances 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000006427 angiogenic response Effects 0.000 description 1
• 238000003975 animal breeding Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003501 anti-edematous effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000003501 co-culture Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 150000004292 cyclic ethers Chemical class 0.000 description 1
• 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000005661 deetherification reaction Methods 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 239000011928 denatured alcohol Substances 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 201000009101 diabetic angiopathy Diseases 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 208000010643 digestive system disease Diseases 0.000 description 1
• 229940079919 digestives enzyme preparation Drugs 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000013024 dilution buffer Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 238000011037 discontinuous sequential dilution Methods 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 235000021186 dishes Nutrition 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000000921 elemental analysis Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 208000018685 gastrointestinal system disease Diseases 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000009931 harmful effect Effects 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 238000004896 high resolution mass spectrometry Methods 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000055590 human KDR Human genes 0.000 description 1
• 208000013653 hyalitis Diseases 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 230000000521 hyperimmunizing effect Effects 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 150000002611 lead compounds Chemical class 0.000 description 1
• 229910000464 lead oxide Inorganic materials 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
• 210000001365 lymphatic vessel Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000004579 marble Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• AFHUVHLESVXVRA-UHFFFAOYSA-N methyl 4-(4-oxo-1h-indeno[1,2-c]pyrazol-3-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=NNC2=C1C(=O)C1=CC=CC=C12 AFHUVHLESVXVRA-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002900 methylcellulose Drugs 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• KFXWHISGWUQZOM-UHFFFAOYSA-N n-(1,4-dihydroindeno[1,2-c]pyrazol-6-yl)-2-morpholin-4-ylacetamide Chemical compound C=1C=C(C=2NN=CC=2C2)C2=CC=1NC(=O)CN1CCOCC1 KFXWHISGWUQZOM-UHFFFAOYSA-N 0.000 description 1
• ICIRPNVMCONZPK-UHFFFAOYSA-N n-(3-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-6-yl)cyclohexanecarboxamide Chemical compound C1CCCCC1C(=O)NC(C=1)=CC=C(C=2NN=3)C=1CC=2C=3C1=CC=CC=C1 ICIRPNVMCONZPK-UHFFFAOYSA-N 0.000 description 1
• JSZRBPPYGULUDX-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-2,2,3,3,3-pentafluoropropanamide Chemical compound C1=CC(NC(=O)C(F)(F)C(F)(F)F)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 JSZRBPPYGULUDX-UHFFFAOYSA-N 0.000 description 1
• XETMBUQUOIXFLJ-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-4-(2-methoxyphenyl)piperazine-1-carboxamide Chemical compound COC1=CC=CC=C1N1CCN(C(=O)NC=2C=CC(=CC=2)C=2C3=C(C4=CC=CC=C4C3)NN=2)CC1 XETMBUQUOIXFLJ-UHFFFAOYSA-N 0.000 description 1
• LAODNKXWYHJXGB-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-4-phenylpiperazine-1-carboxamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)N(CC1)CCN1C1=CC=CC=C1 LAODNKXWYHJXGB-UHFFFAOYSA-N 0.000 description 1
• VOFFRUZZTSNUTK-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-n',n'-diethylpropane-1,3-diamine Chemical compound C1=CC(NCCCN(CC)CC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 VOFFRUZZTSNUTK-UHFFFAOYSA-N 0.000 description 1
• PCWXUIPBYMFSBD-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-n',n'-dimethylpropane-1,3-diamine Chemical compound C1=CC(NCCCN(C)C)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 PCWXUIPBYMFSBD-UHFFFAOYSA-N 0.000 description 1
• MHDLJHOJPQXZRU-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-n',n'-dipropylethane-1,2-diamine Chemical compound C1=CC(NCCN(CCC)CCC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 MHDLJHOJPQXZRU-UHFFFAOYSA-N 0.000 description 1
• QDNCMJQJMJOTNS-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]-n',n'-dipropylpropane-1,3-diamine Chemical compound C1=CC(NCCCN(CCC)CCC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 QDNCMJQJMJOTNS-UHFFFAOYSA-N 0.000 description 1
• JYCQCRCQFFOBQM-UHFFFAOYSA-N n-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]cyclohexanecarboxamide Chemical compound C=1C=C(C=2C3=C(C4=CC=CC=C4C3)NN=2)C=CC=1NC(=O)C1CCCCC1 JYCQCRCQFFOBQM-UHFFFAOYSA-N 0.000 description 1
• DIQGFDCTEXJGCB-UHFFFAOYSA-N n-[[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]methyl]-n',n'-diethylethane-1,2-diamine;trihydrochloride Chemical compound Cl.Cl.Cl.C1=CC(CNCCN(CC)CC)=CC=C1C1=NNC2=C1CC1=CC=CC=C21 DIQGFDCTEXJGCB-UHFFFAOYSA-N 0.000 description 1
• LGFJRGDZWMSSNM-UHFFFAOYSA-N n-[[4-(1h-[1]benzothiolo[3,2-c]pyrazol-3-yl)phenyl]methyl]-3-imidazol-1-ylpropan-1-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C(C=2C=3SC4=CC=CC=C4C=3NN=2)C=CC=1CNCCCN1C=CN=C1 LGFJRGDZWMSSNM-UHFFFAOYSA-N 0.000 description 1
• LTXQUHZOFBZRSF-UHFFFAOYSA-N n-[[4-(4,5-dihydro-1h-benzo[g]indazol-3-yl)pyridin-2-yl]methyl]formamide Chemical compound C1=NC(CNC=O)=CC(C=2C3=C(C4=CC=CC=C4CC3)NN=2)=C1 LTXQUHZOFBZRSF-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229940127082 non-receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 230000004768 organ dysfunction Effects 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 229920000620 organic polymer Polymers 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 208000002865 osteopetrosis Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229950000964 pepstatin Drugs 0.000 description 1
• 108010091212 pepstatin Proteins 0.000 description 1
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 210000004214 philadelphia chromosome Anatomy 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• NUSQOFAKCBLANB-UHFFFAOYSA-N phthalocyanine tetrasulfonic acid Chemical compound C12=CC(S(=O)(=O)O)=CC=C2C(N=C2NC(C3=CC=C(C=C32)S(O)(=O)=O)=N2)=NC1=NC([C]1C=CC(=CC1=1)S(O)(=O)=O)=NC=1N=C1[C]3C=CC(S(O)(=O)=O)=CC3=C2N1 NUSQOFAKCBLANB-UHFFFAOYSA-N 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
• 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
• 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 229940099511 polysorbate 65 Drugs 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940116317 potato starch Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 210000004986 primary T-cell Anatomy 0.000 description 1
• 230000001023 pro-angiogenic effect Effects 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
• 229940080818 propionamide Drugs 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 230000029983 protein stabilization Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
• 150000003246 quinazolines Chemical class 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 229920005604 random copolymer Polymers 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 150000003346 selenoethers Chemical class 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000011775 sodium fluoride Substances 0.000 description 1
• 235000013024 sodium fluoride Nutrition 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 108010087686 src-Family Kinases Proteins 0.000 description 1
• 102000009076 src-Family Kinases Human genes 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 239000012089 stop solution Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 150000003900 succinic acid esters Chemical class 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 150000003899 tartaric acid esters Chemical class 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000006276 transfer reaction Methods 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 208000021331 vascular occlusion disease Diseases 0.000 description 1
• 230000004865 vascular response Effects 0.000 description 1
• 230000004862 vasculogenesis Effects 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 229910000166 zirconium phosphate Inorganic materials 0.000 description 1